Treating Tobacco Addiction and Other Behaviors with Psilocybin: Exploring Years of Research and What the Future Holds

On the first day of the Cannabis Science Conference in the psychedelics track, Dr. Matthew Johnson presented a keynote address highlighting important results from the past 18 years of his research on the treatment of addiction and other psychiatric disorders using psychedelics. He gave a history of how psychedelics have been used in the past primarily to treat alcoholism and cancer-related distress, explained the recent uptick in interest in studies involving psilocybin and hallucinogens, and gave his vision for future studies.

“I'm excited to present the high rates of success that we've seen so far,” Dr. Johnson explained in a recent interview with Cannabis Science and Technology. “It's been surprisingly effective and research is ongoing, but the things that makes psilocybin different are the high rates of success, and the different way in which it works. That's the thing that's difficult to really digest because it is different than other anti-addiction medications in a lot of ways. In one sense, as I mentioned earlier, it's not a substitution treatment.”

In his presentation, Dr. Johnson outlined several published studies, comparative efficacy trials, and pilots in terms of which psychedelic was used and for which condition, how patients were screened and selected, and the results plus the unexpected outcomes. If we take a step back and look at the commonalities of these promising findings, he asked, what are the common mechanisms? What does an addiction disorder mean in a broad sense? How do reported “mystical experiences” during treatments affect patients’ understanding of themselves and their addictive behaviors?